Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions.

PubWeight™: 1.57‹?› | Rank: Top 4%

🔗 View Article (PMID 15673320)

Published in Kidney Int on February 01, 2005

Authors

Eugenia Nikolsky1, Roxana Mehran, Zoran Lasic, Gary S Mintz, Alexandra J Lansky, Yingbo Na, Stuart Pocock, Manuela Negoita, Issam Moussa, Gregg W Stone, Jeffrey W Moses, Martin B Leon, George Dangas

Author Affiliations

1: Cardiovascular Research Foundation, New York, New York, USA.

Articles citing this

Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol (2011) 3.14

Cancer and renal insufficiency results of the BIRMA study. Br J Cancer (2010) 1.03

Side effects of radiographic contrast media: pathogenesis, risk factors, and prevention. Biomed Res Int (2014) 0.99

Lung cancer and renal insufficiency: prevalence and anticancer drug issues. Lung (2008) 0.98

Acute kidney injury by radiographic contrast media: pathogenesis and prevention. Biomed Res Int (2014) 0.93

Risk of contrast-induced nephropathy in hospitalized patients with cirrhosis. World J Gastroenterol (2009) 0.91

Prevention of contrast-induced nephropathy through a knowledge of its pathogenesis and risk factors. ScientificWorldJournal (2014) 0.90

Periprocedural hemoglobin drop and contrast-induced nephropathy in percutaneous coronary intervention patients. Korean Circ J (2010) 0.87

Contrast-induced nephropathy in interventional cardiology. Int J Nephrol Renovasc Dis (2011) 0.86

Contrast-induced nephropathy: pathogenesis and prevention. Pediatr Nephrol (2009) 0.82

Impact of anemia on contrast-induced nephropathy (CIN) in patients undergoing percutaneous coronary interventions. Int Urol Nephrol (2012) 0.81

Contrast-induced nephropathy following angiography and cardiac interventions. Heart (2016) 0.79

[Contrast induced nephropathy]. Wien Klin Wochenschr (2009) 0.77

Contrast-induced nephropathy in patients with active cancer undergoing contrast-enhanced computed tomography. Support Care Cancer (2015) 0.77

Cardiological Society of India practice guidelines for angiography in patients with renal dysfunction. Indian Heart J (2012) 0.75

Contrast Medium Exposure During Computed Tomography and Risk of Development of End-Stage Renal Disease in Patients With Chronic Kidney Disease: A Nationwide Population-Based, Propensity Score-Matched, Longitudinal Follow-Up Study. Medicine (Baltimore) (2016) 0.75

Postprocedural drop in hematocrit versus contrast-induced nephropathy: eggs or chickens? Kidney Int (2005) 0.75

Impact of low hemoglobin on the development of contrast-induced nephropathy: A retrospective cohort study. Exp Ther Med (2016) 0.75

Cancer and the kidney: dangereoux liasons or price paid for the progress in medicine? Oncotarget (2017) 0.75

Articles by these authors

Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med (2010) 22.04

Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med (2011) 15.70

A controlled trial of renal denervation for resistant hypertension. N Engl J Med (2014) 14.22

Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med (2003) 13.29

Strategies for multivessel revascularization in patients with diabetes. N Engl J Med (2012) 10.79

A prospective natural-history study of coronary atherosclerosis. N Engl J Med (2011) 10.66

Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98

From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61

Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation (2002) 8.51

Diagnostic accuracy of fractional flow reserve from anatomic CT angiography. JAMA (2012) 6.96

Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J (2005) 6.86

Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet (2007) 6.77

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol (2011) 6.35

Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves. N Engl J Med (2015) 6.28

Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med (2012) 6.27

Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med (2008) 5.86

A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol (2004) 5.67

Bivalirudin for patients with acute coronary syndromes. N Engl J Med (2006) 5.49

Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med (2007) 5.37

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation (2011) 5.09

Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med (2012) 4.47

Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol (2012) 4.29

Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med (2002) 4.25

Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med (2013) 4.16

Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet (2012) 4.02

Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization And Urgent Intervention Triage Strategy (ACUITY) substudy. Circulation (2010) 3.95

From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94

Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85

Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet (2013) 3.74

Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA (2012) 3.71

Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis. J Am Coll Cardiol (2004) 3.67

Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial. Circulation (2013) 3.64

Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol (2006) 3.45

Long-term outcome of percutaneous coronary intervention for chronic total occlusions. JACC Cardiovasc Interv (2011) 3.38

Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol (2011) 3.37

Intravenous platelet blockade with cangrelor during PCI. N Engl J Med (2009) 3.31

Health-related quality of life after transcatheter or surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results from the PARTNER (Placement of AoRTic TraNscathetER Valve) Trial (Cohort A). J Am Coll Cardiol (2012) 3.29

Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med (2010) 3.27

Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet (2013) 3.17

A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol (2005) 3.15

Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA (2007) 3.07

Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet (2011) 3.00

Multiple testing, cumulative radiation dose, and clinical indications in patients undergoing myocardial perfusion imaging. JAMA (2010) 2.97

Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. N Engl J Med (2015) 2.97

Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation (2007) 2.95

Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA (2004) 2.89

Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study. Circulation (2006) 2.88

Can we improve the statistical analysis of stroke trials? Statistical reanalysis of functional outcomes in stroke trials. Stroke (2007) 2.86

In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol (2010) 2.85

Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet (2009) 2.82

Comparison of clinical interpretation with visual assessment and quantitative coronary angiography in patients undergoing percutaneous coronary intervention in contemporary practice: the Assessing Angiography (A2) project. Circulation (2013) 2.81

Bivalirudin started during emergency transport for primary PCI. N Engl J Med (2013) 2.80

Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol (2012) 2.78

Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation (2005) 2.78

Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound study. Circulation (2003) 2.72

Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis: results from the placement of aortic transcatheter valves (PARTNER) trial (Cohort B). Circulation (2012) 2.71

Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet (2007) 2.67

Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). J Am Coll Cardiol (2013) 2.64